---
title: Challenging Clinical Perspectives in TypeÂ 2 Diabetes with Tirzepatide, a First-in-Class
  Twincretin
date: '2023-10-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37824027/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231012180840&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist ('twincretin')-a
  single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1)
  and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS
  clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated
  with unprecedented reductions in HbA1c, clinically significant weight loss and other
  metabolic benefits, combined with low rates of hypoglycaemia across a wide range
  of ...
disable_comments: true
---
Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist ('twincretin')-a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits, combined with low rates of hypoglycaemia across a wide range of ...